Last updated on April 24, 2014 at 0:10 EDT

Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting

October 21, 2013

Presentations to Highlight Data from Two Recently Completed Clinical Trials for Company’s Lead Rheumatoid Arthritis Products

CHICAGO, Oct. 21, 2013 /PRNewswire/ — Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced today that data from two recently completed clinical trials for its lead product will be presented during the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting to be held October 25 – 30, in San Diego, CA at the San Diego Convention Center.

“We’re encouraged by the data each of these studies have generated as it provides additional validation for our unique approach to delivering a broad dosing range of methotrexate to patients with rheumatoid arthritis,” remarked Terri Shoemaker, President and CEO of Medac Pharma, Inc. “Our primary goal is to provide this extremely underserved patient population with a more personalized delivery technique to managing their disease, and we believe we’re on track for accomplishing that through our unique approach.”

The posters will highlight Medac Pharma Inc.’s rationale for the development of its lead product by presenting data on relative bioavailability and ease of self-administration.

Monday, October 28, 2013:

    Title:                        Successful Self-Administration of
                                  Methotrexate In Rheumatoid
                                  Arthritis Patients Using a
                                  Prefilled Autoinjector Pen

    Time:                         Available: 9:00 a.m. PT - 11:00
                                  a.m. PT

    Poster:                      Abstract #1354

    Location:                     Exhibit Hall B2-C-D (8:30 a.m. PT
                                  - 4:00 p.m. PT)

                                  Subcutaneous Administration Of
                                  Methotrexate With a Prefilled
                                  Autoinjector Pen Results In a
                                  Higher Relative Bioavailability
                                  Compared To Oral Administration Of
    Title:                        Methotrexate

    Time:                         Available: 9:00 a.m. PT - 11:00
                                  a.m. PT

    Poster:                      Abstract # 1355

    Location:                     Exhibit Hall B2-C-D (8:30 a.m. PT
                                  - 4:00 p.m. PT)

About Medac Pharma, Inc.

Medac Pharma, Inc. is the wholly owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.

Medac Pharma Inc. is focused on developing therapies with the potential to make meaningful differences in patients’ lives. The company’s approach is to improve existing agents by enhancing the mode of delivery, addressing safety profiles and inventing ways to maximize efficacy.

For more information, please visit www.medacpharma.com.

For Media:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Medac Pharma, Inc.

Source: PR Newswire